These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12858473)

  • 1. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.
    Pham T; Van Der Heijde D; Lassere M; Altman RD; Anderson JJ; Bellamy N; Hochberg M; Simon L; Strand V; Woodworth T; Dougados M;
    J Rheumatol; 2003 Jul; 30(7):1648-54. PubMed ID: 12858473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
    Pham T; van der Heijde D; Altman RD; Anderson JJ; Bellamy N; Hochberg M; Simon L; Strand V; Woodworth T; Dougados M
    Osteoarthritis Cartilage; 2004 May; 12(5):389-99. PubMed ID: 15094138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OARSI/OMERACT criteria of being considered a candidate for total joint replacement in knee/hip osteoarthritis as an endpoint in clinical trials evaluating potential disease modifying osteoarthritic drugs.
    Dougados M; Hawker G; Lohmander S; Davis AM; Dieppe P; Maillefert JF; Gossec L
    J Rheumatol; 2009 Sep; 36(9):2097-9. PubMed ID: 19738220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis.
    Gossec L; Hawker G; Davis AM; Maillefert JF; Lohmander LS; Altman R; Cibere J; Conaghan PG; Hochberg MC; Jordan JM; Katz JN; March L; Mahomed N; Pavelka K; Roos EM; Suarez-Almazor ME; Zanoli G; Dougados M
    J Rheumatol; 2007 Jun; 34(6):1432-5. PubMed ID: 17552070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI.
    Bellamy N; Bell MJ; Goldsmith CH; Pericak D; Walker V; Raynauld JP; Torrance GW; Tugwell P; Polisson R
    Osteoarthritis Cartilage; 2005 Feb; 13(2):104-10. PubMed ID: 15694571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values.
    Escobar A; Gonzalez M; Quintana JM; Vrotsou K; Bilbao A; Herrera-Espiñeira C; Garcia-Perez L; Aizpuru F; Sarasqueta C
    Osteoarthritis Cartilage; 2012 Feb; 20(2):87-92. PubMed ID: 22155074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.
    Smith TO; Hawker GA; Hunter DJ; March LM; Boers M; Shea BJ; Christensen R; Guillemin F; Terwee CB; Williamson PR; Dodd S; Roos EM; Loeser RF; Schnitzer TJ; Kloppenburg M; Neogi T; Ladel CH; Kalsi G; Kaiser U; Buttel TW; Ashford AE; Mobasheri A; Arden NK; Tennant A; Hochberg MC; de Wit M; Tugwell P; Conaghan PG
    J Rheumatol; 2019 Aug; 46(8):981-989. PubMed ID: 30647185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III.
    Bellamy N; Kirwan J; Boers M; Brooks P; Strand V; Tugwell P; Altman R; Brandt K; Dougados M; Lequesne M
    J Rheumatol; 1997 Apr; 24(4):799-802. PubMed ID: 9101522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
    Bingham CO; Bird SR; Smugar SS; Xu X; Tershakovec AM
    Osteoarthritis Cartilage; 2008 Nov; 16(11):1289-93. PubMed ID: 18514551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low adherence to exercise may have influenced the proportion of OMERACT-OARSI responders in an integrated osteoarthritis care model: secondary analyses from a cluster-randomised stepped-wedge trial.
    Moseng T; Dagfinrud H; van Bodegom-Vos L; Dziedzic K; Hagen KB; Natvig B; Røtterud JH; Vlieland TV; Østerås N
    BMC Musculoskelet Disord; 2020 Apr; 21(1):236. PubMed ID: 32284049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making.
    Bliddal H; Christensen R
    Expert Opin Pharmacother; 2009 Aug; 10(11):1793-804. PubMed ID: 19537998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative.
    Dougados M; Leclaire P; van der Heijde D; Bloch DA; Bellamy N; Altman RD
    Osteoarthritis Cartilage; 2000 Nov; 8(6):395-403. PubMed ID: 11069723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Inverse OARSI-OMERACT Criteria Is a Valid Indicator of the Clinical Worsening of Knee Osteoarthritis: Data From the Osteoarthritis Initiative.
    Driban JB; Harkey MS; Price LL; Lo GH; McAlindon TE
    J Rheumatol; 2021 Mar; 48(3):442-446. PubMed ID: 32541081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-pharmacological approaches for the treatment of osteoarthritis.
    Rannou F; Poiraudeau S
    Best Pract Res Clin Rheumatol; 2010 Feb; 24(1):93-106. PubMed ID: 20129203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs.
    Brandt KD; Mazzuca SA
    Arthritis Rheum; 2005 Nov; 52(11):3349-59. PubMed ID: 16258927
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement.
    Tubach F; Ravaud P; Baron G; Falissard B; Logeart I; Bellamy N; Bombardier C; Felson D; Hochberg M; van der Heijde D; Dougados M
    Ann Rheum Dis; 2005 Jan; 64(1):29-33. PubMed ID: 15208174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the adhesion to the EULAR and OARSI recommendations for the treatment of knee and hip osteoarthritis in current practice].
    Van Linthoudt D
    Praxis (Bern 1994); 2009 Dec; 98(24):1429-35. PubMed ID: 19953468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responders to Exercise Therapy in Patients with Osteoarthritis of the Hip: A Systematic Review and Meta-Analysis.
    Teirlinck CH; Verhagen AP; Reijneveld EAE; Runhaar J; van Middelkoop M; van Ravesteyn LM; Hermsen L; de Groot IB; Bierma-Zeinstra SMA
    Int J Environ Res Public Health; 2020 Oct; 17(20):. PubMed ID: 33050412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design.
    Ravaud P; Giraudeau B; Logeart I; Larguier JS; Rolland D; Treves R; Euller-Ziegler L; Bannwarth B; Dougados M
    Ann Rheum Dis; 2004 Jun; 63(6):703-8. PubMed ID: 15140778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical activity for osteoarthritis management: a randomized controlled clinical trial evaluating hydrotherapy or Tai Chi classes.
    Fransen M; Nairn L; Winstanley J; Lam P; Edmonds J
    Arthritis Rheum; 2007 Apr; 57(3):407-14. PubMed ID: 17443749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.